DCPH
NASDAQDeciphera Pharmaceuticals Inc.
Latest news
25 items- SECSEC Form 15-12G filed by Deciphera Pharmaceuticals Inc.15-12G - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form EFFECT filed by Deciphera Pharmaceuticals Inc.EFFECT - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- INSIDEREVP & Chief Medical Officer Sherman Matthew L was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERChief Financial Officer Kelly Thomas Patrick was granted 34,157 shares and returned 72,029 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERSVP, Chief Development Officer Pitman Jama was granted 20,163 shares and returned 53,951 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERDirector Friedman Franklin Stuart closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERSEC Form 4 filed by Director Kelley Susan L.4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDEREVP & Chief Scientific Officer Dhanak Dashyant was granted 25,913 shares and returned 184,088 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERSEC Form 4 filed by Director Martin John Richard4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERChief Commercial Officer Martin Daniel C. was granted 20,163 shares and returned 43,951 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERDirector Walsh Dennis Leo closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERSEC Form 4 filed by Director Bristol James Arthur4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERSEC Form 4 filed by Director Squarer Ron4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERSEC Form 4 filed by Director Allen Patricia L4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERPresident and CEO Hoerter Steven L. was granted 286,075 shares and returned 286,075 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- INSIDERSEC Form 4 filed by Director Benz Edward J. Jr4 - Deciphera Pharmaceuticals, Inc. (0001654151) (Issuer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form S-8 POS filed by Deciphera Pharmaceuticals Inc.S-8 POS - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
- SECSEC Form POS AM filed by Deciphera Pharmaceuticals Inc.POS AM - Deciphera Pharmaceuticals, Inc. (0001654151) (Filer)
DCPH FAQ
7 questionsWhat does Deciphera Pharmaceuticals Inc. do?
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and...Where does DCPH stock trade?
Deciphera Pharmaceuticals Inc. (DCPH) is listed on NASDAQ.What sector and industry is DCPH in?
Deciphera Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Deciphera Pharmaceuticals Inc. go public?
Deciphera Pharmaceuticals Inc. (DCPH) completed its IPO in 2017.What are analysts saying about DCPH?
Deciphera Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from JP Morgan: Neutral with a $1400.00 price target on 2023-11-20. Recent price targets range from $600.00 to $2500.00.What companies are similar to DCPH?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DCPH side-by-side with any of them on Quantisnow.How can I track DCPH on Quantisnow?
Quantisnow aggregates Deciphera Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DCPH to receive live email and push alerts on every new disclosure.